Market Overview

The Rising Popularity of Legal Cannabis Products in a Variety of Businesses


The Rising Popularity of Legal Cannabis Products in a Variety of Businesses News Commentary

PR Newswire

NEW YORK, August 1, 2018 /PRNewswire/ --

According to recent data compiled by Research And Markets, the North American legal cannabis market value is projected to reach around USD 35 Billion by 2023, expanding at a CAGR of 27.1%. The North American legal cannabis market reached a value of over USD 8 Billion in 2017. The research indicates that cannabis is gaining prominence in North America due to increasing acceptance of products for both recreational and medical uses. Research and development in the field of medical usage of cannabis is expected to create a positive business growth environment necessary for a growing industry. CLS Holdings USA Inc. (OTC:CLSH), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Aurora Cannabis Inc. (OTC:ACBFF), Terra Tech Corp. (OTC:TRTC), Auxly Cannabis Group Inc. (OTC:CBWTF)

In Canada, the use and purchase of cannabis has been legalized recently for people over the age of 18 years. A report by Deloitte indicates that Canadians are expected to spend as much as $7.17 billion on cannabis products in 2019. "Canada is in a unique position as the first G7 country on the cusp of legalizing recreational cannabis," said Mark Whitmore, Vice Chair and Global Leader Deloitte Private. "The move to legalize recreational cannabis has sparked a wave of innovation and entrepreneurship, similar to Canada's technology sector, which will create jobs for Canadians, new opportunities for businesses and revenues for governments."

CLS Holdings USA Inc. (OTCQB:CLSH) announced last week the, "appointment of Frank Tarantino as Chief Financial Officer. Mr. Tarantino brings big four public accounting and private and public company management and financial expertise, which will be extremely beneficial in leading the Company through its next phase in organic growth and acquisitions.

Mr. Tarantino stated, "I am pleased to join CLS post acquisition of Oasis Cannabis and look forward to working with the executive team in its strategic transition into vertically integrated operations, and expanding its operations in Nevada and other key markets."

Mr. Tarantino has more than 18 years of executive management experience in public and private companies and six years of experience in public accounting. Prior to joining CLS, Mr. Tarantino was the COO/CFO of Wild Things, an outdoor clothing manufacturer and retailer serving the US Military and foreign governments. Prior to Wild Things, Mr. Tarantino worked as the Vice President of Finance at Cornerstone Brands, an acquisition and holding company concentrating on high end, online and direct mail retailers. Mr. Tarantino was involved with several acquisitions and managed the company's bank syndicated credit line, which peaked at $135 million. Mr. Tarantino also worked on raising capital for both Wild Things and Cornerstone Brands. In the early stages of his career, Mr. Tarantino worked as an auditor for Coopers and Lybrand, now Pricewaterhouse Coopers, in the Boston office where he concentrated on auditing financial institutions, banks, broker dealers and institutional investors.

Mr. Tarantino earned a BS in Accounting and Finance from Babson College, Wellesley, MA and earned his Certified Public Accountant Certificate from the State of Massachusetts."

Mr. Lamadrid has elected to resign due to personal considerations. CLS Chief Executive Officer Jeff Binder stated, "We thank Mr. Lamadrid for working with us as we expanded into vertically integrated operations, and seeing us through the entire process of acquiring Oasis."

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals, Inc. announced on July 9th, 2018 the initiation of a multi-national, randomized, double blind placebo controlled Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X (CONNECT-FX). The CONNECT-FX trial will evaluate the efficacy and safety of ZYN002 (CBD Gel) in children ages three to 17 with full mutation Fragile X syndrome (FXS). FXS is a genetic condition that causes intellectual disability, behavioral and learning challenges and is the most common known single gene cause of autism spectrum disorder. Top line results are expected in the second half of 2019. The CONNECT-FX study is a multi-national randomized, double-blind, placebo-controlled, 14-week study that will assess the efficacy and safety of ZYN002 for the treatment of children and adolescents with FXS. Approximately 200 male and female patients with Fragile X syndrome, confirmed with the full mutation of the FMR1 gene, will be enrolled at approximately 20 clinical sites in the United States, Australia, and New Zealand. "We are excited to initiate CONNECT-FX, the first-of-its-kind clinical study evaluating transdermally-delivered ZYN002 as a treatment for the debilitating behaviors associated with Fragile X syndrome," said Armando Anido, Chairman and Chief Executive Officer of Zynerba. "We look forward to demonstrating the clinical effects of ZYN002 in treating some of the most common behavioral symptoms of Fragile X syndrome. If successful, ZYN002 has the potential to become the first product indicated for the treatment of behavioral symptoms of Fragile X syndrome and help address the ongoing needs of the children and families impacted by this syndrome."

Aurora Cannabis Inc. (OTCQX:ACBFF), headquartered in Edmonton, Alberta, with funded capacity in excess of 570,000 kg per year and sales and operations in 14 countries across five continents, is one of the world's largest and leading cannabis companies. Aurora Cannabis Inc. ("Aurora" or the "Company") announced on July 23rd, 2018 that it has obtained a Health Canada Dealer's License ("Dealer's License") under the Controlled Drugs and Substances Act for its EU GMP certified Aurora Mountain facility in Alberta. The new license will allow Aurora additional opportunities to produce, assemble, and sell cannabis oils and future novel, derivative products from Aurora Mountain, Furthermore, the license provides additional opportunities to transport cannabis products for import from and export to international markets, subject to applicable regulations. A dealer's license is also critical for expanding research and development capacity as it provides the potential for working with cannabinoids and their derivatives not covered under an ACMPR license. This will enable Aurora and its subsidiaries to drive innovation in the form of marketable intellectual property, and new value-added products. "Aurora Mountain is our third facility to be granted a Dealer's License by Health Canada, and this milestone is fundamental to bolstering our supply chain across Canada and around the world," said Terry Booth, Chief Executive Officer of Aurora. "Being able to more freely transport and export cannabis oils, derivatives and concentrates allows us to develop new products that respond to market demand in a variety of regulatory frameworks in different countries."\

Terra Tech Corp. (OTCQX:TRTC) operates through multiple subsidiary businesses including: Blüm, IVXX Inc., Edible Garden, and MediFarm LLC. Terra Tech Corp. ("Terra Tech" or the "Company"), a vertically integrated cannabis-focused agriculture company, announced on July 26th, 2018 that it has secured a 25% ownership stake in The Healing Tree Collective, Inc., a cannabis dispensary operator based in California. On July 23, 2018, The Healing Tree Collective was awarded a retail permit associated with a facility on W. Pendleton Ave, Santa Ana, by the City of Santa Ana. The remaining 75% of The Healing Tree Collective, and therefore the associated permit, is held by other members of the collective, with whom Terra Tech partnered in order to complete the permit application process. Under the terms of the agreement between Terra Tech and the other members of The Healing Tree Collective, Inc, Terra Tech covered the costs of the permit application and Terra Tech's wholly-owned subsidiary, Black Oak Gallery, will be responsible for managing all of the facility's operations, including hiring decisions. The facility is located at 3222 W. Pendleton Ave, Santa Ana, California, an area of Santa Ana in which Terra Tech did not previously have a presence. Derek Peterson, Chief Executive Officer of Terra Tech, commented, "We are pleased to have leveraged our know-how and experience in the Santa Ana market to secure this retail permit with The Healing Tree Collective, without needing to expend significant time or resources to do so. As the cannabis market continues to mature we expect these permits to become more valuable. We believe that maximizing our first mover advantage by securing a stake in this permit may lead to additional revenue opportunities in the medium and longer term."

Auxly Cannabis Group Inc. (OTCQX:CBWTF) is a collective of entrepreneurs with a passion for the cannabis industry past, present and future. Auxly Cannabis Group Inc. ("Auxly" or the "Company") announced July 23rd, 2018 that its wholly-owned subsidiary, Kolab Project Inc. ("Kolab" or "Kolab Project"), has received its sales licence from Health Canada, pursuant to the Access to Cannabis for Medical Purposes Regulations. Kolab will source the best cannabis products from the entire Auxly cultivation platform and through partnerships with acclaimed growers from around the world. Among these will be Kolab's facility in Carleton Place, Ontario, where the second phase of construction has been completed and is expected to be commissioned for cultivation in the coming months. Once phase three is completed, the facility will total 20,000 sq. ft., have over 20 local employees and be a centre of excellence for the production of medical-grade cannabis. "The sales licence marks a significant milestone in Kolab's development of a different kind of company - one that rethinks the patient experience," said Andrew Rock, Chief Operating Officer of Kolab. "As a craft grower, we are passionate about our product and take our commitment as a licensed producer seriously. Through our focus on research and development, we will produce the highest quality medical-grade cannabis. I am grateful to our team for the dedication and hard work that got us here and look forward to building a community that enriches the health and wellness of Canadian patients."

Subscribe Now! Watch us report LIVE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For CLS Holdings USA Inc. financial news dissemination and PR services, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: .

Media Contact:




View Comments and Join the Discussion!